Investigational Drug Information for Nirmatrelvir

What is the development status for investigational drug Nirmatrelvir?

Nirmatrelvir is an investigational drug.

There have been 23 clinical trials for Nirmatrelvir. The most recent clinical trial was a Phase 3 trial, which was initiated on January 21^st 2023.

The most common disease conditions in clinical trials are COVID-19, Coronavirus Infections, and Tachycardia. The leading clinical trial sponsors are Pfizer, Xiangao Jiang, and Sponsor GmbH.

There is one US patent protecting this investigational drug and forty-four international patents.

Summary for Nirmatrelvir

US Patents	1
International Patents	44
US Patent Applications	4
WIPO Patent Applications	3
Japanese Patent Applications	0
Clinical Trial Progress	Phase 3 (2023-01-21)
Vendors	27

Recent Clinical Trials for Nirmatrelvir

Title	Sponsor	Phase
RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms	Kanecia Obie Zimmerman	Phase 2
A Study to Learn About the Study Medicine Called Nirmatrelvir/Ritonavir in People Who Are Healthy Volunteers Co-administered the Medicine Rosuvastatin	Pfizer	Phase 1
Clinical Study for the Efficacy and Safety of Ropeginterferon Alfa-2b in Adult COVID-19 Patients With Comorbidities	National Taiwan University Hospital	Phase 2/Phase 3

See all Nirmatrelvir clinical trials

Clinical Trial Summary for Nirmatrelvir

Top disease conditions for Nirmatrelvir

Top clinical trial sponsors for Nirmatrelvir

See all Nirmatrelvir clinical trials

US Patents for Nirmatrelvir

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
nirmatrelvir

International Patents for Nirmatrelvir

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
nirmatrelvir	Argentina	AR123111	2040-09-03
nirmatrelvir	Australia	AU2021266232	2040-09-03
nirmatrelvir	Australia	AU2022202158	2040-09-03
nirmatrelvir	Australia	AU2022221493	2040-09-03